Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.

Li Q, Kuang HY, Wu YH, Lu TW, Yi QJ.

Medicine (Baltimore). 2019 May;98(20):e15632. doi: 10.1097/MD.0000000000015632.

2.

Role of ambrisentan (selective endothelin-A receptor antagonist) on cigarette smoke exposure induced cognitive impairment in Danio rerio.

Muthuraman A, Nafisa K, Sowmya MS, Arpitha BM, Choedon N, Sandy CD, Rishitha N, Johurul I.

Life Sci. 2019 Apr 1;222:133-139. doi: 10.1016/j.lfs.2019.03.002. Epub 2019 Mar 4.

PMID:
30844374
3.

A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.

Wang S, Yu M, Zheng X, Dong S.

Drug Deliv. 2018 Nov;25(1):1898-1909. doi: 10.1080/10717544.2018.1523257.

4.

Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?

Correale M, Ferraretti A, Monaco I, Grazioli D, Di Biase M, Brunetti ND.

Vasc Health Risk Manag. 2018 Oct 4;14:253-264. doi: 10.2147/VHRM.S133921. eCollection 2018. Review.

5.

Hepatic safety of ambrisentan alone and in combination with tadalafil: a post-hoc analysis of the AMBITION trial.

Patel KR, Blair CJ, Tislow JD.

Pulm Circ. 2018 Oct-Dec;8(4):2045894018797273. doi: 10.1177/2045894018797273. Epub 2018 Aug 20.

6.

Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4-aminopyridine.

Ribeiro Baptista B, Petitpain N, Gomez E, Yelehé-Okouma M, Valentin S, Guillaumot A, Chabot F, Chaouat A.

Fundam Clin Pharmacol. 2019 Feb;33(1):127-129. doi: 10.1111/fcp.12396. Epub 2018 Jul 15.

PMID:
29956855
7.

Current and Future Treatments for Persistent Pulmonary Hypertension in the Newborn.

Pedersen J, Hedegaard ER, Simonsen U, Krüger M, Infanger M, Grimm D.

Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):392-406. doi: 10.1111/bcpt.13051. Epub 2018 Jul 19. Review.

PMID:
29855164
8.

A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.

Bedan M, Grimm D, Wehland M, Simonsen U, Infanger M, Krüger M.

Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):103-113. doi: 10.1111/bcpt.13033. Epub 2018 Jun 5. Review.

9.

Antiproteinuric effect of an endothelin-1 receptor antagonist in puromycin aminonucleoside-induced nephrosis in rat.

Kino J, Tsuji S, Kitao T, Akagawa Y, Yamanouchi S, Kimata T, Kaneko K.

Pediatr Res. 2018 May;83(5):1041-1048. doi: 10.1038/pr.2018.11. Epub 2018 Feb 21.

PMID:
29360807
10.

German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2018 Feb;72(2):155-168. doi: 10.1055/s-0043-123035. Epub 2018 Jan 16.

11.

Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report).

Takahashi T, Hayata S, Kobayashi A, Onaka Y, Ebihara T, Hara T.

Clin Drug Investig. 2018 Mar;38(3):219-229. doi: 10.1007/s40261-017-0602-4.

PMID:
29282676
12.
13.

Evaluation system for arrhythmogenic potential of drugs using human-induced pluripotent stem cell-derived cardiomyocytes and gene expression analysis.

Higa A, Hoshi H, Yanagisawa Y, Ito E, Morisawa G, Imai JI, Watanabe S, Takagi M.

J Toxicol Sci. 2017;42(6):755-761. doi: 10.2131/jts.42.755.

14.

Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia.

Schroeder T, Piantadosi CA, Natoli MJ, Autmizguine J, Cohen-Wolkowieczs M, Hamilton KL, Bell C, Klawitter J, Christians U, Irwin DC, Noveck RJ.

Clin Pharmacol Ther. 2018 May;103(5):888-898. doi: 10.1002/cpt.860. Epub 2017 Oct 17.

15.

Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).

Shapiro S, Torres F, Feldman J, Keogh A, Allard M, Blair C, Gillies H, Tislow J, Oudiz RJ.

Respir Med. 2017 May;126:84-92. doi: 10.1016/j.rmed.2017.03.025. Epub 2017 Mar 29.

16.

Ambrisentan: a review of its use in pulmonary arterial hypertension.

Rivera-Lebron BN, Risbano MG.

Ther Adv Respir Dis. 2017 Jun;11(6):233-244. doi: 10.1177/1753465817696040. Epub 2017 Apr 20. Review.

17.

From the Cover: MechanisticInsights in Cytotoxic and Cholestatic Potential of the Endothelial Receptor Antagonists Using HepaRG Cells.

Burbank MG, Sharanek A, Burban A, Mialanne H, Aerts H, Guguen-Guillouzo C, Weaver RJ, Guillouzo A.

Toxicol Sci. 2017 Jun 1;157(2):451-464. doi: 10.1093/toxsci/kfx062.

18.

Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.

Duo-Ji MM, Long ZW.

Int J Cardiol. 2017 May 1;234:90-98. doi: 10.1016/j.ijcard.2016.12.092. Epub 2017 Jan 5.

PMID:
28233631
19.

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.

Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators.

Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30.

20.

Supplemental Content

Loading ...
Support Center